Ned Pagliarulo

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.

Treatment with cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.

One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset seizures.

The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s therapy for a rare neurodevelopmental disorder.

An HHS spokesperson confirmed Prasad's reappointment as chief medical and scientific officer, one month after his surprising return to the agency as CBER director.

The British drugmaker’s commitment comes just as some of its pharma peers question their presence in the U.K. amid a widening row there over pricing polices.

The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity drug Zepbound.

AveXis will be folded into Novartis' quality organization as a result of a scandal involving altered testing data for the company's gene therapy Zolgensma.